A number of other firms have also recently commented on ICLR. Analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of ICON plc from $18.50 to $24.00 in a research note to investors on Wednesday, April 25th. They now have a “hold” rating on the stock. Separately, analysts at Wells Fargo & Co. (NYSE: WFC) upgraded shares of ICON plc from a “market perform” rating to an “outperform” rating in a research note to investors on Wednesday, April 25th. Finally, analysts at Sterne Agee upgraded shares of ICON plc from a “neutral” rating to a “buy” rating in a research note to investors on Tuesday, April 24th.
ICON plc traded up 0.05% on Friday, hitting $21.80. ICON plc has a 52-week low of $15.03 and a 52-week high of $26.22. The company has a market cap of $1.311 billion and a price-to-earnings ratio of 57.34.
ICON plc last posted its quarterly earnings results on Tuesday, April 24th. The company reported $0.15 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.15. The company’s quarterly revenue was up 10.0% on a year-over-year basis. On average, analysts predict that ICON plc will post $0.28 earnings per share next quarter.
ICON plc (ICON) is a contract research organization (CRO), providing outsourced development services on a worldwide basis to the pharmaceutical, biotechnology and medical device industries.